(HealthDay News) – A closed-loop insulin delivery system can improve glucose control and reduce hypoglycemia in patients with type 1 diabetes, compared with sensor-augmented pump therapy, according to a study published online Sept. 17 in the New England Journal of Medicine to coincide with presentation at the annual meeting of the European Association for the Study of Diabetes in Stockholm, Sweden.
Hood Thabit, MD, PhD, from the University of Cambridge in the United Kingdom, and colleagues compared closed-loop insulin delivery with sensor-augmented pump therapy in 58 patients with type 1 diabetes under free-living home conditions. Thirty-three adults used the closed-loop system day and night, while 25 children and adolescents used the system overnight for a 12-week period. The control sensor-augmented pump therapy was used for a similar period of time.
The researchers found that the proportion of time the glucose level was in the target range was significantly higher when adults used the closed-loop system as opposed to the sensor-augmented pump. Similar results were seen for children and adolescents. Use of the closed-loop system also yielded significantly lower mean glucose levels and lower area under the curve for the period when the glucose level was <63mg/dL for both adults and children and adolescents.
“Among patients with type 1 diabetes, 12-week use of a closed-loop system, as compared with a sensor-augmented pump therapy, improved glucose control, reduced hypoglycemia, and in adults, resulted in a lower glycated hemoglobin level,” conclude the authors.